Subtype
Head and Neck Squamous Cell Carcinoma
CI-CAN-00002836HNSCC · SCCHNExplore in graph →
592 active trials6 approved drugs53 evidence items
- NCIt
- C34447
- OncoTree
- HNSC
- DOID
- 5520
- UMLS CUI
- C1168401
- MeSH
- D000077195
- Other
- 1 more code
Loading cancer entity…
Subtype
CI-CAN-00002836HNSCC · SCCHNExplore in graph →
Clinical trials
1,589 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (247)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07044635 | Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.(RAD RAPTORS) | recruiting | Phase 2 | 42 | University of UtahOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06336941 | "Ultra-High Frequency intraOral UltraSonography of the TONgue" (HOUSTON)(HOUSTON) | recruiting | N/A | 400 | University of PisaOTHER | 1 | Feb 25, 2026 |
| clinicaltrials |
| NCT06678724 | Establishment of a Microfluidic Based Liquid Biopsy Platform for Recurrent/Metastatic Head and Neck Cancers Prognostication Using NK Cell IFN-γ Expression and CTM Correlation With DS-SACA Chip | recruiting | — | 30 | National Taiwan University HospitalOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT06305962 | 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors | recruiting | Early Phase 1 | 30 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07063212 | A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) | recruiting | Phase 2 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07030257 | Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | Tasca TherapeuticsINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT05031910 | Virtual Reality 3D-Surgery Modeling to Enhance Head and Neck Cancer Surgery Quality | recruiting | N/A | 160 | Thomas Jefferson UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06778863 | A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation(GUARDIAN-101) | recruiting | Phase 1 | 90 | Clasp Therapeutics, Inc.INDUSTRY | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07405645 | Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy(MRg-FUS) | recruiting | N/A | 20 | University of VirginiaOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06636734 | Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial | recruiting | Phase 2 | 28 | Emory UniversityOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07402525 | Postoperative Radiotherapy for Early-stage Oral Tongue Squamous Cell Carcinoma Patients With Risk Factors: a Prospective, Multicenter, Randomized Controlled, Open-labelled Trial(PORT-ESTER) | recruiting | N/A | 190 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT01473784 | Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck | recruiting | N/A | 600 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT03740256 | Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors(VISTA) | recruiting | Phase 1 | 45 | Baylor College of MedicineOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05962242 | HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma(HN001) | recruiting | Phase 2 | 90 | University of VirginiaOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05894083 | A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze) | recruiting | Phase 2 | 150 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06319963 | A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer | recruiting | Phase 1 / Phase 2 | 72 | Theravectys S.A.INDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07151040 | Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors(ODIN) | recruiting | Phase 1 / Phase 2 | 43 | One-carbon Therapeutics ABINDUSTRY | 3 | Jan 28, 2026 | clinicaltrials |
| NCT07371611 | Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma | recruiting | Phase 3 | 104 | Qunxing Li,MDOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05553782 | Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers | recruiting | Early Phase 1 | 30 | Brigham and Women's HospitalOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07254585 | SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 70 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07348211 | First in Human Study of SIM0610 in Solid Tumors(SIM0610-101) | recruiting | Phase 1 | 260 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 23, 2026 | clinicaltrials |
| NCT06194656 | Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 81 | Shanghai Institute Of Biological ProductsINDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07343271 | Dual-energy CT vs. MRI in the Evaluation of Squamous Cell Carcinomas of the Oral Cavity and Oropharynx(DECT-CEco) | recruiting | — | 30 | University Hospital, Strasbourg, FranceOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06999187 | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas | recruiting | Phase 1 | 96 | Dren BioINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03215719 | Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma | recruiting | Phase 2 | 120 | NYU Langone HealthOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07274852 | A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | recruiting | Phase 1 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT04528420 | Optimised Early Management of Squamous Cell Carcinoma of the Head and Neck Cancer(OPTINECK) | recruiting | N/A | 138 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT07232524 | A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | recruiting | Phase 1 | 16 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07190755 | Impact of Patient-Reported Outcomes for Symptom Monitoring in Patients Followed for Head and Neck Squamous Cell Carcinoma (HNSCC)(WEBNECK) | recruiting | N/A | 192 | Centre Henri BecquerelOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06645808 | PET-imaging of Two Vartumabs in Patients With Solid Tumors(VARTUTRACE) | recruiting | Early Phase 1 | 32 | Var2 PharmaceuticalsINDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT05183048 | Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma | recruiting | Early Phase 1 | 14 | University of Alabama at BirminghamOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT06022029 | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.(ON-5001) | recruiting | Phase 1 | 168 | OncoNano Medicine, Inc.INDUSTRY | 2 | Dec 24, 2025 | clinicaltrials |
| NCT06659146 | Thermotherapy in Addition to SOC Palliative Radiotherapy(ThermoRad wIRA) | recruiting | N/A | 60 | King's College LondonOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT06606028 | Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma | recruiting | — | 250 | University of California, San FranciscoOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT03556228 | VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | recruiting | Phase 1 / Phase 2 | 242 | VM Oncology, LLCINDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT05793151 | Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy(ENDURE) | recruiting | N/A | 532 | Medical University of South CarolinaOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT06107686 | A Study of YL202 in Selected Patients With Advanced Solid Tumors | recruiting | Phase 2 | 200 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT05333523 | Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.(PRIMO) | recruiting | Phase 3 | 242 | Radboud University Medical CenterOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06332755 | Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC(LB-LR1109) | recruiting | Phase 1 | 76 | LG ChemINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07081984 | Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors | recruiting | Phase 1 | 12 | TherornaINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07106827 | A Study of GV20-0251 in Advanced or Refractory Solid Tumors | recruiting | Phase 1 | 10 | West China HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06088381 | Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)(SAVAL) | recruiting | Phase 2 | 61 | University of Maryland, BaltimoreOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05902988 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 200 | Volastra Therapeutics, Inc.INDUSTRY | 1 | Nov 4, 2025 | clinicaltrials |
| NCT06914999 | Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer | recruiting | Early Phase 1 | 20 | Emory UniversityOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT06597565 | A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC | recruiting | Phase 2 | 43 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT06699212 | A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases(ECLIPSE) | recruiting | Phase 3 | 412 | Rakuten Medical, Inc.INDUSTRY | 3 | Oct 15, 2025 | clinicaltrials |
| NCT04370587 | A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 30 | ImmVira Pharma Co. LtdINDUSTRY | 2 | Oct 8, 2025 | clinicaltrials |
| NCT05945875 | Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer | recruiting | Phase 1 | 40 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 3, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 27, 2026source: clinicaltrials